The AVATAR Group was established in 2007 by Professor Claire Rickard. Today, AVATAR is a respected independent research group specializing in highly credible scientific vascular access device research.
The AVATAR Group undertakes a significant program of clinical trials, laboratory, systematic review and knowledge translation research including health economics, both in Australia and internationally.The group is currently undertaking several NHMRC funded research trials: The RSVP Trial Replacement of intravascular administration sets at Standard Versus Prolonged intervals; The SAVE Trial Securing All intraVenous devices Effectively; the PISCES Trial Peripherally InSerted CEntral catheter Securement; and, Innovation to improve the experience and outcomes of paediatric central venous access devices: the e-Vascular Access Passport.
Our administrative base is at Griffith University, Brisbane, Australia, and we work in partnership with researchers from many other universities and healthcare organizations in Australia and internationally.
No patient or carer wants to experience painful stabs to insert an intravenous (IV) catheter, or for their IV catheter to become blocked and useless, or to develop a serious infection from the IV catheter. At AVATAR, we don't think these things should happen either.
Our mission is to make vascular access complications history.
We have 6 key focus areas: